Expression of tenascin-C splice variants in normal and bullous keratopathy human corneas

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 7, 1998, Pages 1135-1142

  Ljubimov, Alexander V ^a   Saghizadeh, Mehrnoosh ^a   Spirin, Konstantin S ^a   Khin, Htwe L ^a   Lewin, Sheryl L ^a   Zardi, Luciano ^b   Bourdon, Mario A ^c   Kenney, M Cristina ^a  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c La Jolla Institute for Experimental Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; TENASCIN;

ADULT; AGED; APHAKIA; ARTICLE; CELL ADHESION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; KERATOPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; BLOTTING, WESTERN; CORNEA; CORNEAL DISEASES; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE PROBES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TENASCIN;

EID: 0031832208     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Liu E, Slomovic AR. Indications for penetrating keratoplasty in Canada, 1986-1995. Cornea. 1997;16:414-419.
2. Ljubimov AV, Burgeson RE, Butkowski RJ, et al. Extracellular matrix alterations in human corneas with bullous keratopathy. Invest Ophthalmol Vis Sci. 1996;37:997-1007.
3. Waring GO. Posterior collagenous layer of the cornea: ultrastructural classification of abnormal collagenous tissue posterior to Descemet's membrane in 30 cases. Arch Ophthalmol. 1982;100: 122-134.
4. Kay EP, Cheung C-C, Jester JV, Nimni ME, Smith RE. Type I collagen and fibronectin synthesis by retrocorneal fibrous membrane. Invest Ophthalmol Vis Sci. 1982;22:200-212.
5. Tuberville A, Wood TO, Hasty K. The "posterior collagenous layer" does contain collagen [ARVO Abstracts]. Invest Ophthalmol Vis Sci. 1989;30:S336. Abstract nr 11.
6. Kenney MC, Chwa M. Abnormal extracellular matrix in corneas with pseudophakic bullous keratopathy. Cornea. 1990;9:115-121.
7. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983;43:2796-2805.
8. Erickson HP. Tenascin-C, tenascin-R, and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol. 1993;5:869-876.
9. Chiquet-Ehrismann R, Hagios C, Schenk S. The complexity in regulating the expression of tenascins. Bioessays. 1995;17:873-878.
10. Crossin KL. Tenascin: a multifunctional extracellular matrix protein with a restricted distribution in development and disease. J Cell Biochem. 1996;61:592-598.
11. Chiquet-Ehrismann R, Matsuoka Y, Hofer U, Spring J, Bernasconi C, Chiquet M. Tenascin variants: differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul. 1991;2:927-938.
12. Deryugina EI, Bourdon MA. Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci. 1996;109:643-652.
13. Shrestha P, Sumitomo S, Lee CH, et al. Tenascin: growth and adhesion modulation-extracellular matrix degrading function: an in vitro study. Eur J Cancer B Oral Oncol. 1996;32B:106-113.
14. Bartsch U. The extracellular matrix molecule tenascin-C: expression in vivo and functional characterization in vitro. Prog Neurobiol. 1996;49:145-168.
15. Dömes U, Taylor J, Xiao Z, Lochter A, Montag D, Schachner M. Distinct effects of recombinant tenascin-C domains on neuronal cell adhesion, growth cone guidance, and neuronal polarity. J Neurosci Res. 1996;43:420-438.
16. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin, J Cell Biol. 1991;115: 1127-1136.
17. Chung CY, Erickson HP. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol. 1994;126:539-548.
18. Husmann K, Carbonetto S, Schachner M. Distinct sites on tenascin-C mediate repellent or adhesive interactions with different neuronal cell types. Cell Adhes Commun. 1995;3:293-310.
19. Erickson HP, Bourdon MA. An extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol. 1989;5:71-92.
20. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev. 1992;6:1821-1831.
21. Tucker RP, Hammarback JA, Jenrath DA, Mackie EJ, Xu Y. Tenascin expression in the mouse: in situ localization and induction in vitro by bFGF. J Cell Sci. 1993;104:69-76.
22. Sakai T, Kawakatsu H, Ohta M, Saito M. Tenascin induction in tenascin nonproducing carcinoma cell lines in vivo and by TGF-β1 in vitro. J Cell Physiol. 1994;159:561-572.
23. LaFleur DW, Fagin JA, Forrester JS, Rubin SA, Sharifi BG. Cloning and characterization of alternatively spliced isoforms of rat tenascin. J Biol Chem. 1994;269:20757-20763.
24. Tervo T, van Setten G-B, Lehto I, Tervo K, Tarkkanen A, Virtanen I. Immunohistochemical demonstration of tenascin in the normal human limbus with special reference to trabeculectomy. Ophthalmic Res. 1990;22:128-133.
25. Ataullah SM, Maseruka H, Bonshek RE, Zardi L. Tenascin-C (TN-C) variants in pseudophakic/aphakic bullous keratopathy (PBK/ABK) human corneas [ARVO Abstracts]. Invest Ophthalmol Vis Sci 1997;38:S504. Abstract nr 2325.
26. Saghizadeh M, Khin HL, Bourdon MA, Kenney MC, Ljubimov AV. Novel splice variants of human tenascin-C mRNA identified in normal and bullous keratopathy corneas. Cornea 1998. In press.
27. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403-410.
28. Ausubel FM, Brent R, Kingston RE, et al., eds. Current Protocols in Molecular Biology, Volume 1. New York, NY: John Wiley & Sons; 1994;2.9A-3.10.
29. Balza E, Siri A, Ponassi M, et al. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett. 1993;332:39-43.
30. Siri A, Knäuper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem. 1995;270: 8650-8654.
31. Myint E, Brown DJ, Ljubimov AV, Kyaw M, Kenney MC. Cleavage of human corneal type VI collagen α3 chain by matrix metalloproteinase-2. Cornea. 1996;15:490-496.
32. Zhou L, Yue BY, Twining SS, Sugar J, Feder RS. Expression of wound healing and stress-related proteins in keratoconus corneas. Curr Eye Res. 1996;15:1124-1131.
33. Tuori A, Virtanen I, Aine E, Uusitalo H. The expression of tenascin and fibronectin in keratoconus, scarred and normal human cornea. Graefes Arch Clin Exp Ophthalmol. 1997;235:222-229.
34. Wilson KE, Langdon SP, Lessels AM, Miller WR. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Br J Cancer. 1996;74:999-1004.
35. Siri A, Allemanni G, Gaggero B, Zardi L. Different human tenascin-C variants in the extracellular matrix of cultured human fibroblasts. Biochem Cell Biol. 1996;74:863-866.
36. Leprini A, Querze G, Zardi L. Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect Dev Neurobiol. 1994;2:117-123.
37. Fischer D, Brown-Ludi M, Schulthess T, Chiquet-Ehrismann R. Concerted action of tenascin-C domains in cell adhesion, antiadhesion and promotion of neunte outgrowth J Cell Sci. 1997; 110:1513-1522.
38. Prieto AL, Anderson-Fisone C, Crossin KL. Characterization of multiple adhesive and counteradhesive domains in the extracellular matrix protein cytotactin. J Cell Biol. 1992;119:663-678.
39. 3 integrins. J Cell Sci. 1993;105:1001-1012.
40. Joshi P, Chung CY, Aukhil I, Erickson HP. Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin. J Cell Sci. 1993;106:389-400.
41. Vaughan L, Zisch AH, Weber P, et al. Cellular receptors for tenascin. In: Koide H, Hayashi T, eds. Extracellular Matrix in the Kidney. Basel, Switzerland: Karger; 1994;107:80-84.
42. Zisch AH, D'Alessandri L, Rauscht B, Falchetto R, Winterhalter KH, Vaughan L. Neuronal cell adhesion molecule contactin/F11 binds to tenascin via its immunoglobulin-like domains. J Cell Biol. 1992; 119:203-213.
43. Kaplony A, Zimmermann DR, Fischer R, Imhof BA, Odermatt BF, Winterhalter KH, et al. Tenascin Mr 220,000 isoform expression correlates with corneal cell migration. Development. 1991;112: 605-614.
44. Kenney MC, Nesburn AB, Burgeson RE, Butkowski RJ, Ljubimov AV. Abnormalities of the extracellular matrix in keratoconus corneas. Cornea. 1997;16:345-351.
45. Uusitalo M. Immunohistochemical localization of chondroitin sulfate proteoglycan and tenascin in the human eye compared with the HNK-1 epitope. Graefes Arch Clin Exp Ophthalmol. 1994;232: 657-665.
46. Maseruka H, Bonshek RE, Tullo AB. Tenascin-C expression in normal, inflamed, and scarred human corneas. Br J Ophthalmol. 1997;81:677-682.
47. Lass JH, Greiner JV, Reinhart WJ, Medcalf SK, Glonek T. Phosphatic metabolism and corneal edema. Cornea. 1991;10:346-353.
48. Raphael B, Lange RB, Wood T, McLaughlin BJ. Growth of human corneal endothelium on altered Descemet's membrane. Cornea. 1992;11:242-249.
49. Mackie EJ. Tenascin in connective tissue development and pathogenesis. Perspect Dev Neurobiol. 1994;2:125-132.
50. Tremble P, Chiquet-Ehrismann R, Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell. 1994;5: 439-453.
51. Rosenbaum JT, Planck ST, Huang XN, Rich L, Ansel JC. Detection of mRNA for the cytokines, interleukin-1α and interleukin-8, in corneas from patients with pseudophakic bullous keratopathy. Invest Ophthalmol Vis Sci. 1995;36:2151-2155.
52. Rettig WJ., Erickson HP, Albino AP, Garin-Chesa P. Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways. J Cell Sci. 1994; 107:487-497.
53. Borsi L, Allemanni G, Gaggero B, Zardi L. Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed cells. Int J Cancer. 1996;66:632-635.
54. Chiquet-Ehrismann R, Tannheimer M, Koch M, et al. Tenascin-C expression by fibroblasts is elevated in stressed collagen gels. J Cell biol. 1994;127:2093-2101.
55. Chiquet M, Matthisson M, Koch M, Tannheimer M, Chiquet-Ehrismann R. Regulation of extracellular matrix synthesis by mechanical stress. Biochem Cell Biol. 1996;74:737-744.
56. Faissner A, Steindler D. Boundaries and inhibitory molecules in developing neural tissues. Glia. 1995;13:233-254.
57. Betz P, Nerlich A, Tubel J, Penning R, Eisenmenger W. Localization of tenascin in human skin wounds - an immunohistochemical study, Int J Legal Med. 1993;105:325-328.
58. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol. 1996;179: 321-325.
59. Maguen E, Alba SA, Burgcson RE, et al. Alterations of corneal extracellular matrix following multiple refractive procedures: a clinical and immunohistochemical study. Cornea. 1997;16:675-682.
60. Maguen E, Kenney MC, Alba SA, Ljubimov AV. Extracellular matrix changes in scars of human radial keratotomy corneas. [ARVO Abstracts], Invest Ophthalmol Vis Sci. 1997;38:S209. Abstract nr 1010.